Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters

Abstract

In late 2019, an outbreak of a severe respiratory disease caused by an emerging coronavirus, SARS-CoV-2, resulted in high morbidity and mortality in infected humans. Complete understanding of COVID-19, the multi-faceted disease caused by SARS-CoV-2, requires suitable small animal models, as does the development and evaluation of vaccines and antivirals. Since age-dependent differences of COVID-19 were identified in humans, we compared the course of SARS-CoV-2 infection in young and aged Syrian hamsters. We show that virus replication in the upper and lower respiratory tract was independent of the age of the animals. However, older hamsters exhibited more pronounced and consistent weight loss. In situ hybridization in the lungs identified viral RNA in bronchial epithelium, alveolar epithelial cells type I and II, and macrophages. Histopathology revealed clear age-dependent differences, with young hamsters launching earlier and stronger immune cell influx than aged hamsters. The latter developed conspicuous alveolar and perivascular edema, indicating vascular leakage. In contrast, we observed rapid lung recovery at day 14 after infection only in young hamsters. We propose that comparative assessment in young versus aged hamsters of SARS-CoV-2 vaccines and treatments may yield valuable information, as this small-animal model appears to mirror age-dependent differences in human patients.

References 40

1. 1.

   Liu Y., Mao B., Liang S., Yang J.W., Lu H.W., Chai Y.H., Wang L., Zhang L., Li Q.H., Zhao L., et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur. Respir. J. 2020;55.

   Not in our library10.1183/13993003.01112-2020

2. 2.

   Paules C.I., Marston H.D., Fauci A.S. Coronavirus Infections-More Than Just the Common Cold. JAMA. 2020.

   Not in our library10.1001/jama.2020.0757

3. 3.

   de Wit E., van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016;14:523-534.

   Not in our library10.1038/nrmicro.2016.81

4. 4.

   Zhang Y.Z., Holmes E.C. A Genomic Perspective on the Origin and Emergence of SARS-CoV-2. Cell. 2020;181:223-227.

   Not in our library10.1016/j.cell.2020.03.035

5. 5.

   Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708-1720.

   Not in our library10.1056/nejmoa2002032

6. 6.

   Nikolich-Zugich J., Knox K.S., Rios C.T., Natt B., Bhattacharya D., Fain M.J. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience. 2020;42:505-514.

   Not in our library10.1007/s11357-020-00186-0

7. 7.

   Liu K., Chen Y., Lin R., Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J. Infect. 2020;80:e14-e18.

   Not in our library10.1016/j.jinf.2020.03.005

8. 8.

   Banerjee A., Pasea L., Harris S., Gonzalez-Izquierdo A., Torralbo A., Shallcross L., Noursadeghi M., Pillay D., Sebire N., Holmes C., et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. Lancet. 2020;395:1715-1725.

   Not in our library10.1016/s0140-6736(20)30854-0

9. 9.

   Lakdawala S.S., Menachery V.D. The search for a COVID-19 animal model. Science. 2020;368:942-943.

   Not in our library10.1126/science.abc6141

10. 10.

    Yuan L., Tang Q., Cheng T., Xia N. Animal models for emerging coronavirus: progress and new insights. Emerg. Microbes Infect. 2020;9:949-961.

    Not in our library10.1080/22221751.2020.1764871

11. 11.

    Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271-280.e278.

    Not in our library10.1016/j.cell.2020.02.052

12. 12.

    Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J. Virol. 2020;94.

    Not in our library10.1128/jvi.00127-20

13. 13.

    Pach S., Ngoc Nguyen T., Trimpert J., Kunec D., Wolber G. ACE2-Variants Indicate Potential SARS-CoV-2-Susceptibility in Animals: An Extensive Molecular Dynamics Study. bioRxiv. 2020.

    Not in our library10.1101/2020.05.14.092767

14. 14.

    Munster V.J., Feldmann F., Williamson B.N., van Doremalen N., Perez-Perez L., Schulz J., Meade-White K., Okumura A., Callison J., Brumbaugh B., et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature. 2020.

    Not in our library10.1038/s41586-020-2324-7

15. 15.
    Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model · 2020

    No notice
16. 16.
    Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques · 2020

    No notice
17. 17.

    Yu P., Qi F., Xu Y., Li F., Liu P., Liu J., Bao L., Deng W., Gao H., Xiang Z., et al. Age-related rhesus macaque models of COVID-19. Anim. Model. Exp. Med. 2020;3:93-97.

    Not in our library10.1002/ame2.12108

18. 18.

    Dinnon K.H., Leist S.R., Schäfer A., Edwards C.E., Martinez D.R., Montgomery S.A., West A., Yount B.L., Hou Y.J., Adams L.E., et al. A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures. bioRxiv. 2020.

    Not in our library10.1101/2020.05.06.081497

19. 19.
    Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy · 2020

    No notice
20. 20.

    Bao L., Deng W., Huang B., Gao H., Liu J., Ren L., Wei Q., Yu P., Xu Y., Qi F., et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020.

    Not in our library10.1038/s41586-020-2312-y

21. 21.

    Gong S.R., Bao L.L. The battle against SARS and MERS coronaviruses: Reservoirs and Animal Models. Anim. Model. Exp. Med. 2018;1:125-133.

    Not in our library10.1002/ame2.12017

22. 22.

    Gretebeck L.M., Subbarao K. Animal models for SARS and MERS coronaviruses. Curr. Opin. Virol. 2015;13:123-129.

    Not in our library10.1016/j.coviro.2015.06.009

23. 23.
    Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2 · 2020

    No notice
24. 24.

    Kim Y.I., Kim S.G., Kim S.M., Kim E.H., Park S.J., Yu K.M., Chang J.H., Kim E.J., Lee S., Casel M.A.B., et al. Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. Cell Host Microbe. 2020;27:704-709.e702.

    Not in our library10.1016/j.chom.2020.03.023

25. 25.

    Subbarao K., Roberts A. Is there an ideal animal model for SARS? Trends Microbiol. 2006;14:299-303.

    Not in our library10.1016/j.tim.2006.05.007

26. 26.

    Roberts A., Vogel L., Guarner J., Hayes N., Murphy B., Zaki S., Subbarao K. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J. Virol. 2005;79:503-511.

    Not in our library10.1128/jvi.79.1.503-511.2005

27. 27.

    Sia S.F., Yan L.M., Chin A.W.H., Fung K., Choy K.T., Wong A.Y.L., Kaewpreedee P., Perera R., Poon L.L.M., Nicholls J.M., et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020.

    Not in our library10.1038/s41586-020-2342-5

28. 28.

    Chan J.F., Zhang A.J., Yuan S., Poon V.K., Chan C.C., Lee A.C., Chan W.M., Fan Z., Tsoi H.W., Wen L., et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 2020.

    Not in our library10.1093/cid/ciaa325

29. 29.

    Thao T.T.N., Labroussaa F., Ebert N., V’Kovski P., Stalder H., Portmann J., Kelly J., Steiner S., Holwerda M., Kratzel A., et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature. 2020.

    Not in our library10.1038/s41586-020-2294-9

30. 30.

    Wölfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Müller M.A., Niemeyer D., Jones T.C., Vollmar P., Rothe C., et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465-469.

    Not in our library10.1038/s41586-020-2196-x

31. 31.

    Nakamura T., Karakida N., Dantsuka A., Ichii O., Elewa Y.H.A., Kon Y., Nagasaki K.I., Hattori H., Yoshiyasu T. Effects of a mixture of medetomidine, midazolam and butorphanol on anesthesia and blood biochemistry and the antagonizing action of atipamezole in hamsters. J. Vet. Med. Sci. 2017;79:1230-1235.

    Not in our library10.1292/jvms.17-0210

32. 32.

    Dietert K., Gutbier B., Wienhold S.M., Reppe K., Jiang X., Yao L., Chaput C., Naujoks J., Brack M., Kupke A., et al. Spectrum of pathogen- and model-specific histopathologies in mouse models of acute pneumonia. PLoS ONE. 2017;12:e0188251.

    Not in our library10.1371/journal.pone.0188251

33. 33.

    Erickson N.A., Gruber A.D., Mundhenk L. The Family of Chloride Channel Regulator, Calcium-activated Proteins in the Feline Respiratory Tract: A Comparative Perspective on Airway Diseases in Man and Animal Models. J. Comp. Pathol. 2020;174:39-53.

    Not in our library10.1016/j.jcpa.2019.10.193

34. 34.

    Reppe K., Radunzel P., Dietert K., Tschernig T., Wolff T., Hammerschmidt S., Gruber A.D., Suttorp N., Witzenrath M. Pulmonary immunostimulation with MALP-2 in influenza virus-infected mice increases survival after pneumococcal superinfection. Infect. Immun. 2015;83:4617-4629.

    Not in our library10.1128/iai.00948-15

35. 35.

    Schauer A.E., Klassert T.E., von Lachner C., Riebold D., Schneeweiss A., Stock M., Muller M.M., Hammerschmidt S., Bufler P., Seifert U., et al. IL-37 Causes Excessive Inflammation and Tissue Damage in Murine Pneumococcal Pneumonia. J. Innate Immun. 2017;9:403-418.

    Not in our library10.1159/000469661

36. 36.
    Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR · 2020

    Expression of concern
37. 37.

    Zivcec M., Safronetz D., Haddock E., Feldmann H., Ebihara H. Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). J. Immunol. Methods. 2011;368:24-35.

    Not in our library10.1016/j.jim.2011.02.004

38. 38.

    Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov A., et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. NJEM. 2020.

    Not in our library10.1056/nejmoa2015432

39. 39.

    Hui K.P.Y., Cheung M.-C., Perera R.A.P.M., Ng K.-C., Bui C.H.T., Ho J.C.W., Ng M.M.T., Kuok D.I.T., Shih K.C., Tsao S.-W., et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir. Med. 2020.

    Not in our library10.1016/s2213-2600(20)30193-4

40. 40.
    Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development · 2020

    No notice

Cited by papers we hold 9

• SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals · 2021
  No notice
• SARS-CoV-2 disease severity and transmission efficiency is increased for airborne compared to fomite exposure in Syrian hamsters · 2021
  No notice
• Thymus Degeneration and Regeneration · 2021
  Not checked
• Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model · 2021
  Not checked
• Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates · 2021
  Not checked
• mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents · 2021
  No notice
• A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge · 2020
  No notice
• I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People · 2020
  No notice
• Animals and SARS‐CoV‐2: Species susceptibility and viral transmission in experimental and natural conditions, and the potential implications for community transmission · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.